Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Li, Lili ^a   Li, Chen ^a   Mao, Haitao ^a   Du, Zhenfang ^a   Chan, Wai Yee ^a   Murray, Paul ^b   Luo, Bing ^c   Chan, Anthony T C ^a   Mok, Tony S K ^a   Chan, Francis K L ^a   Ambinder, Richard F ^d   Tao, Qian ^a,d  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c QINGDAO UNIVERSITY   (China)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; HOMEODOMAIN PROTEIN; MIXED FUNCTION OXIDASE; NERVE PROTEIN; ONCOPROTEIN; SIGNAL PEPTIDE; SLIT HOMOLOG 2 PROTEIN; TET1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXA9; ZNF382 PROTEIN, HUMAN;

CHEMISTRY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; ENZYME ACTIVE SITE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; NEOPLASM; PHYSIOLOGICAL FEEDBACK; PROTEIN DOMAIN; TUMOR CELL LINE;

CATALYTIC DOMAIN; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DNA-BINDING PROTEINS; DOWN-REGULATION; EPIGENESIS, GENETIC; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MIXED FUNCTION OXYGENASES; NEOPLASMS; NERVE TISSUE PROTEINS; PROTEIN DOMAINS; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTORS;

EID: 84971328511     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26591     Document Type: Article

References (58)

1. Jones, P. A., Baylin, S. B. The epigenomics of cancer. Cell 128, 683-692, doi: 10.1016/j.cell.2007.01.029 (2007).
2. Schubeler, D. Function and information content of DNA methylation. Nature 517, 321-326, doi: 10.1038/nature14192 (2015).
3. You, J. S., Jones, P. A. Cancer genetics and epigenetics: two sides of the same coin? Cancer cell 22, 9-20, doi: 10.1016/j. ccr.2012.06.008 (2012).
4. Hamidi, T., Singh, A. K., Chen, T. Genetic alterations of DNA methylation machinery in human diseases. Epigenomics 7, 247-265, doi: 10.2217/epi.14.80 (2015).
5. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558, doi: 10.1126/science.1235122 (2013).
6. Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935, doi: 10.1126/science.1170116 (2009).
7. Jin, S. G. et al. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer research 71, 7360-7365, doi: 10.1158/0008-5472.CAN-11-2023 (2011).
8. Haffner, M. C. et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2, 627-637 (2011).
9. Kudo, Y. et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer science 103, 670-676, doi: 10.1111/j.1349-7006.2012.02213.x (2012).
10. Bachman, M. et al. 5-Hydroxymethylcytosine is a predominantly stable DNA modification. Nature chemistry 6, 1049-1055, doi: 10.1038/nchem.2064 (2014).
11. Lian, C. G. et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150, 1135-1146, doi: 10.1016/j. cell.2012.07.033 (2012).
12. Tan, L., Shi, Y. G. Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development 139, 1895-1902, doi: 10.1242/dev.070771 (2012).
13. Guo, J. U., Su, Y., Zhong, C., Ming, G. L., Song, H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145, 423-434, doi: 10.1016/j.cell.2011.03.022 (2011).
14. Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. The New England journal of medicine 360, 2289-2301, doi: 10.1056/NEJMoa0810069 (2009).
15. Konstandin, N. et al. Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia. Leukemia 25, 1649-1652, doi: 10.1038/leu.2011.134 (2011).
16. Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer cell 20, 11-24, doi: 10.1016/j.ccr.2011.06.001 (2011).
17. Ito, S. et al. Role of Tet proteins in 5 mC to 5 hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466, 1129-1133, doi: 10.1038/nature09303 (2010).
18. Yamaguchi, S., Shen, L., Liu, Y., Sendler, D., Zhang, Y. Role of Tet1 in erasure of genomic imprinting. Nature 504, 460-464, doi: 10.1038/nature12805 (2013).
19. Wu, H. et al. Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 473, 389-393, doi: 10.1038/nature09934 (2011).
20. Dawlaty, M. M. et al. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell 9, 166-175, doi: 10.1016/j.stem.2011.07.010 (2011).
21. Spruijt, C. G. et al. Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell 152, 1146-1159, doi: 10.1016/j. cell.2013.02.004 (2013).
22. Yang, H. et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 32, 663-669, doi: 10.1038/onc.2012.67 (2013).
23. Neri, F. et al. TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway. Oncogene, doi: 10.1038/onc.2014.356 (2014).
24. Sun, M. et al. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America 110, 9920-9925, doi: 10.1073/pnas.1305172110 (2013).
25. Hsu, C. H. et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell reports 2, 568-579, doi: 10.1016/j.celrep.2012.08.030 (2012).
26. Wu, B. K., Brenner, C. Suppression of TET1-dependent DNA demethylation is essential for KRAS-mediated transformation. Cell reports 9, 1827-1840, doi: 10.1016/j.celrep.2014.10.063 (2014).
27. Song, S. J. et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 154, 311-324, doi: 10.1016/j.cell.2013.06.026 (2013).
28. Wang, Y., Zhang, Y. Regulation of TET protein stability by calpains. Cell reports 6, 278-284, doi: 10.1016/j.celrep.2013.12.031 (2014).
29. Muller, T. et al. Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. The American journal of pathology 181, 675-683, doi: 10.1016/j.ajpath.2012.04.017 (2012).
30. Huang, Y. et al. Loss of nuclear localization of TET2 in colorectal cancer. Clin Epigenetics 8, 9, doi: 10.1186/s13148-016-0176-7 (2016).
31. Li, L. et al. Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes. Epigenomics 7, 155-173, doi: 10.2217/epi.14.79 (2015).
32. Huang, Y., Rao, A. Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet 30, 464-474, doi: 10.1016/j.tig.2014.07.005 (2014).
33. Neri, F. et al. TET1 is controlled by pluripotency-associated factors in ESCs and downmodulated by PRC2 in differentiated cells and tissues. Nucleic acids research, doi: 10.1093/nar/gkv392 (2015).
34. Ciccarone, F. et al. Poly(ADP-ribosyl)ation is involved in the epigenetic control of TET1 gene transcription. Oncotarget 5, 10356-10367, doi: 10.18632/oncotarget.1905 (2014).
35. Gambichler, T. et al. Decreased expression of ten-eleven translocation 2 protein is associated with progressive disease and death in patients with mucosis fungoides. Br J Dermatol, doi: 10.1111/bjd.14174 (2015).
36. Park, J. L. et al. Decrease of 5 hmC in gastric cancers is associated with TET1 silencing due to with DNA methylation and bivalent histone marks at TET1 CpG island 3?-shore. Oncotarget 6, 37647-37662, doi: 10.18632/oncotarget.6069 (2015).
37. Tsai, K. W. et al. Reduction of global 5-hydroxymethylcytosine is a poor prognostic factor in breast cancer patients, especially for an ER/PR-negative subtype. Breast Cancer Res Treat 153, 219-234, doi: 10.1007/s10549-015-3525-x (2015).
38. Rawluszko-Wieczorek, A. A. et al. Clinical significance of DNA methylation mRNA levels of TET family members in colorectal cancer. Journal of cancer research and clinical oncology, doi: 10.1007/s00432-014-1901-2 (2015).
39. Ichimura, N. et al. Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer. Cancer Prev Res (Phila) 8, 702-711, doi: 10.1158/1940-6207.CAPR-14-0306 (2015).
40. Fan, M., He, X., Xu, X. Restored expression levels of TET1 decrease the proliferation and migration of renal carcinoma cells. Mol Med Rep, doi: 10.3892/mmr.2015.4058 (2015).
41. Cimmino, L. et al. TET1 is a tumor suppressor of hematopoietic malignancy. Nat Immunol 16, 653-662, doi: 10.1038/ni.3148 (2015).
42. Neri, F. et al. Genome-wide analysis identifies a functional association of Tet1 and Polycomb repressive complex 2 in mouse embryonic stem cells. Genome biology 14, R91, doi: 10.1186/gb-2013-14-8-r91 (2013).
43. Okashita, N. et al. PRDM14 promotes active DNA demethylation through the ten-eleven translocation (TET)-mediated base excision repair pathway in embryonic stem cells. Development 141, 269-280, doi: 10.1242/dev.099622 (2014).
44. Williams, K. et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 473, 343-348, doi: 10.1038/nature10066 (2011).
45. Yildirim, O. et al. Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. Cell 147, 1498-1510, doi: 10.1016/j.cell.2011.11.054 (2011).
46. Li, H. P., Leu, Y. W., Chang, Y. S. Epigenetic changes in virus-associated human cancers. Cell Res 15, 262-271, doi: 10.1038/sj. cr.7290295 (2005).
47. Tsai, C. N., Tsai, C. L., Tse, K. P., Chang, H. Y., Chang, Y. S. The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proceedings of the National Academy of Sciences of the United States of America 99, 10084-10089, doi: 10.1073/pnas.152059399 (2002).
48. Ghoshal, K. et al. Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol Cell Biol 22, 8302-8319 (2002).
49. Baylin, S. B., Ohm, J. E. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6, 107-116, doi: 10.1038/nrc1799 (2006).
50. Jin, H. et al. Epigenetic silencing of a Ca(2+ )-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proceedings of the National Academy of Sciences of the United States of America 104, 12353-12358, doi: 10.1073/pnas.0700153104 (2007).
51. Li, L. et al. The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/beta-catenin signaling and silenced in common carcinomas. Oncogene 31, 3901-3912, doi: 10.1038/onc.2011.541 (2012).
52. Li, L. et al. Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting beta-catenin and AKT signaling but frequently methylated in common carcinomas. Cellular and molecular life sciences : CMLS 71, 2179-2192, doi: 10.1007/s00018-013-1485-z (2014).
53. Ying, J. et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 25, 1070-1080, doi: 10.1038/sj.onc.1209154 (2006).
54. Murray, P. G. et al. Epigenetic silencing of a proapoptotic cell adhesion molecule, the immunoglobulin superfamily member IGSF4, by promoter CpG methylation protects Hodgkin lymphoma cells from apoptosis. The American journal of pathology 177, 1480-1490, doi: 10.2353/ajpath.2010.100052 (2010).
55. Wang, Z. et al. Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas. J Transl Med 10, 209, doi: 10.1186/1479-5876-10-209 (2012).
56. Tao, Q. et al. Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis. The American journal of pathology 155, 619-625, doi: 10.1016/S0002-9440(10)65157-7 (1999).
57. Tao, Q. et al. Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Human molecular genetics 11, 2091-2102 (2002).
58. Tao, Q. Cancer research in an era when epigenetics is no longer "epi"-challenges and opportunities. Chinese journal of cancer 32, 1-2, doi: 10.5732/cjc.012.10300 (2013).